Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.

David J. Straus,Monika Długosz-Danecka,Sergey Alekseev,Árpád Illés,Marco Picardi,Ewa Lech-Marańda,Tatyana Feldman,Piotr Smolewski,Kerry J. Savage,Nancy L. Bartlett,Jan Walewski,Radhakrishnan Ramchandren,Pier Luigi Zinzani,Martin Hutchings,Joseph M. Connors,John Radford,Javier Munoz,Won-Seog Kim,Ranjana H. Advani,Stephen M. Ansell,Anas Younes,Harry Miao,Rachael Liu,Keenan Fenton,Andres Forero-Torres,Andrea Gallamini

Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.

2019

7532Background: The phase 3 ECHELON-1 study demonstrated that BV with AVD (A+AVD) was superior to ABVD for the frontline treatment of Stage 3/4 cHL. Maturing data from RATHL and SWOG S0816 show lim...

Keywords:

Pathology
Classical Hodgkin lymphoma
Oncology
Brentuximab vedotin
Internal medicine
Chemotherapy
ABVD
Medicine
Vinblastine
Immunology
Dacarbazine
Chlorambucil
Chemotherapy regimen
Population

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations